Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
Back
Exciting Approval in Europe for HER2-Positive Breast Cancer
Exciting Approval in Europe for HER2-Positive Breast Cancer
Episodes
All
All
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5